In June 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) will convene a meeting of the Cellular, Tissue, and Gene Therapies Advisory ...
I am upgrading Travere Therapeutics, Inc. to a Buy, as the FDA's decision not to hold an AdCom suggests a favorable path for Filspari in FSGS. Filspari's strong sales growth, improved financials, and ...
BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is scheduled for September 27. NurOwn was significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results